Lightnews — Scholar-powered news

Gísli @ipfdoc.bsky.social · 10d

Would be fascinating to do an SR+MA on AF as co-meds in trials vs IMP in trials? 🤔

Gísli @ipfdoc.bsky.social · 10d

For sure there is no dose response really for Pirfenidone some dose response for nintedanib but really good point!

1 1

Gísli @ipfdoc.bsky.social · 10d

No, in London.

Gísli @ipfdoc.bsky.social · 10d

However, another study highlighting the disappearing treatment effect! Check the placebo vs Pirfenidone groups! 😳😳 we really need better drugs to #CureIPF

2 1 2

Gísli @ipfdoc.bsky.social · 10d

TETON-2 data looking good! 96ml of FVC ‘saved’ by inhaled treprostinil at 12 months. Devil will be in detail but all very promising.

1 2 4

Gísli @ipfdoc.bsky.social · 12d

youtu.be/zTs3PDEkB2w

Interesting story.
1) Brexit actually increased migration.
2) Students r source of UKs immigration‘problem’, likely due to our outstanding universities
3) Cumulative asylum seeker retention builds up
4) A ‘hostile environment’ might work but at what cost & for what impact? 😬

UK immigration: What the numbers really show

YouTube video by Sky News

youtu.be

Gísli @ipfdoc.bsky.social · Sep 8

Pogacar vs Vingegaard?
Alcaraz vs Sinner?
Tottenham vs Arsenal?
Giants vs Dodgers?
Nemesis vs motivation?

Gísli @ipfdoc.bsky.social · Sep 7

I think this is a great idea, might be tricky to operationalise.
The current system is breaking if not already broken.
Incentivises research fraud.
Will prevent people seeing the wood because of all the dodgy trees.
#LessIsMore

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Sep 7

PROPOSAL to address issue of publication flooding

Limit individuals to publishing a MAXIMUM of 10 articles/year

🌟 Quality > quantity
🌟 Forced to choose valuable work to which they have meaningfully contributed
🌟 Requires change in academic metrics

@benpatrickwill.bsky.social
@ipfdoc.bsky.social

a man in a suit and tie is standing in front of a door that says change is good

Alt: Captain Holt standing in front of a door that says change is good

media.tenor.com

1 1

Gísli @ipfdoc.bsky.social · Sep 4

This makes me sad (not altogether sure why), but I would like thank #DanielLevy for his hard work over last 25 yrs. The Stadium, European Glory Nights, Great teams, superstar players! 😍 There were some lows I’m sure but I don’t remember those. #COYS

2

Gísli @ipfdoc.bsky.social · Sep 2

Phenomenal result! FIRST positive 52 week study of inhaled therapy in #IPF. Benefits were independent of background therapy! 🤩
Along with Nerandomilast this shows importance of cAMP/PDE4 pathways in fibrosis & opens door 4 other therapies targeting these pathways!
#FutureLooksBright #CureIPF

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Sep 2

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁

Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD

@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

www.theglobeandmail.com/investing/ma...

3 3

Reposted by Gísli

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Sep 2

TETON-2 phase 2 RCT of nebulized treprostinil for IPF 🫁

Positive trial 🗞️
Change in FVC at 52 weeks difference of 95.6mL (!), and 2* endpoints like K-BILD

@ipfdoc.bsky.social @kaminskimed.bsky.social @tkulkarni.bsky.social @jskim8223.bsky.social

www.theglobeandmail.com/investing/ma...

1 4 7

Gísli @ipfdoc.bsky.social · Aug 9

There is a section on Familial Pulmonary Fibrosis, genetics & telomere length, a para on spatial transcriptomics & single cell analysis, also biomarkers. But they haven’t been used add granularity 2 classification. Whilst understandable this will eventually happen, so y rush 2 reclassify now?

Gísli @ipfdoc.bsky.social · Aug 9

Well if anybody can tell me what major paradigm shifting advance in diagnosis or pathogenesis which has substantially altered our understanding of Interstitial Lung Diseases has been included in this document I might change my mind.

1

Gísli @ipfdoc.bsky.social · Aug 8

I think it is as valuable and interesting as this 🤣🤣🤣

Gísli @ipfdoc.bsky.social · Aug 8

Turns out the average time from guideline to implementation is 17 years!!! (So I heard from an expert in that area!)

1 1 3

Gísli @ipfdoc.bsky.social · Aug 8

I think there is no clinical need to update the classification, and I just can’t wait for the next update! 🥱

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Aug 8

What think you all?

@lidahariri.bsky.social @ipfdoc.bsky.social @ild-ipfdoc.bsky.social @rachelkputman.bsky.social @kaminskimed.bsky.social @jskim8223.bsky.social @ats-clinicalprobs.bsky.social @lucillapiccari.bsky.social @killianhurley.bsky.social @emilyfri.bsky.social @leticiakawano.bsky.social

1 1 1

Gísli @ipfdoc.bsky.social · Aug 8

Not if the primary purpose is to promote the journal and the authors! #JustSaying #JobDone

1 2

Gísli @ipfdoc.bsky.social · Aug 8

I’ve just been struck by how structurally (if not functionally) similar broccoli 🥦 is to the lungs 🫁! 😍🤣

1 1

Reposted by Gísli

Kerri Johannson MD MPH @kerrijohannson.bsky.social · Jul 23

This isn’t about Republicans or Democrats or anything to do with politics

This is about men exploiting and committing sexual violence against women and girls

THIS is the issue to bring to the forefront address

1 5

Reposted by Gísli

Waggoner Lab @labwaggoner.bsky.social · Jul 22

People’s brains aged faster during the COVID pandemic — even the uninfected @nature.com
www.nature.com/articles/d41...
@natcomms.nature.com @alirezamnk.bsky.social
@spmic-uon.bsky.social @ipfdoc.bsky.social
www.nature.com/articles/s41...

1 4 7

Reposted by Gísli

Carl T. Bergstrom @carlbergstrom.com · Jul 16

1. Kevin Gross and I just posted a new science-of-science preprint.

This one explores the looming peer review crisis. As many of you know, it's becoming significantly more difficult for journal editors to find scholars willing to serve as peer reviewers for submitted manuscripts.

Will anyone review this paper? Screening, sorting, and the feedback cycles that imperil peer review

Scholarly publishing relies on peer review to identify the best science. Yet finding willing and qualified reviewers to evaluate manuscripts has become an increasingly challenging task, possibly even ...

arxiv.org

23 220 550

Reposted by Gísli

Annals of the ATS @annalsats.bsky.social · Jul 16

Incidence, Prevalence & Mortality of ILDs in Alberta, Canada

Derived, tested case definitions performed well, created a dataset of ILD. Incidence was stable, prevalence increased, mortality decreased for ILD & IPF sub-group
@kerrijohannson.bsky.social
@agrantorser.bsky.social
tinyurl.com/5n7x5w2h

2 2 6

Reposted by Gísli

ATS Blue Journal @atsblueeditor.bsky.social · Jul 17

🎙️ Just published a #NEW episode of Out of the Blue: An AJRCCM Podcast: Approach to the Evaluation and Management of Interstitial Lung Abnormalities
@atscommunity.bsky.social #medsky

Have a listen: outoftheblue.transistor.fm

Out of the Blue: An AJRCCM Podcast

The Out of the Blue podcast takes you out of the pages of the American Journal of Respiratory and Critical Care Medicine and into the minds of the most brilliant researchers in the fields of respirato...

outoftheblue.transistor.fm

3 5

Gísli @ipfdoc.bsky.social · Jul 14

If only all bridges were
like this! #HammersmithBridge #ILoveLondon

1

Gísli @ipfdoc.bsky.social · Jul 13

Quality not quantity!

1 1